Ribociclib (Kisqali®, Novartis, Basel, Switzerland) was approved by the FDA in 2015 based on the results of the Phase III MONALEESA-2 study (NCT01958021) of postmenopausal women with HR+, HER2− advanced or mBC who had not received prior treatment for advanced-stage cancer. Here, ERBB2 is linked to cancer.